Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it has recently received a Notice of Acceptance from the National Medical Products Administration for its drug application concerning "HSK44459 Cream." HSK44459 Cream is a novel, independently developed drug with proprietary intellectual property rights for the treatment of psoriasis and atopic dermatitis. Preclinical research results indicate that the drug has a clear target, reliable efficacy, and a favorable safety profile. As a small-molecule drug with significant development potential, it offers a high benefit/risk ratio for clinical application and holds broad prospects for clinical use. It is expected to become an effective treatment for psoriasis and atopic dermatitis, addressing the current shortage of clinical therapeutic options.